|
市場調查報告書
生物醫藥：2008年第4季的主要動向及活動
Biopharma Quarter: Key Trends and Events of the Fourth Quarter of 2008
|
生物醫藥：2008年第4季的主要動向及活動 是由出版商Decision Resources, Inc.在2009年03月所出版的。
這份英文市場調查報告書包含48 Pages 價格從美金3450起跳。
本報告書內容包括：美國及英國的政治改革及經濟不景氣對生物醫藥產業造成的影響、各國非專利藥品的滲透動向、針對日本生物學名藥產業及中國智慧財產動向的專家觀點等。內容綱要摘記如下：
實施概要
介紹
活動概要
- 政治動向：美國總統選舉的主題
- 經濟：不景氣的影響
- 許可：Latisse進入生活習慣病治療藥領域
- 國際動向：中國藥品製造動向
交易動向
非專利藥品預測：各國政府促進非專利藥品產業發展
- 大型製藥公司進入
- 美國生物學名藥指南
- FDA：因應Heparin Fiasco
- 非專利藥品Plavix打進歐洲市場
- 日本非專利藥品市場開放
策略性預測：全球經濟危機對生物醫藥產業而言是個重大的課題
- 生物科技：金融危機與企業瓦解
- 製藥企業：失去必要改革所需的總體計畫
- 該產業仍需面對的課題
圖表
Abstract
Introduction
2008 came to a close amid political transition in the world' s largest
pharmaceutical market and economic upheaval in all of the world' s markets. Our
review of key events that occurred in the fourth quarter and prominent trends
at play in that time frame refl ects that backdrop and fi nds that companies
in the biopharma industry have an opportunity to move outside of traditional
models to tap new opportunities - and some are making big strides in doing so.
Get the Answers You Need to Shape Your Strategy
- There' s a new administration in Washington. What are the prospects for
expanded care? What are the targets of cost-containment? How do administration
policies present opportunity for the biopharma industry?
- Healthcare is generally regarded as a stable industry in a down economy,
but biopharma is feeling the effects of the global recession. How is access
to healthcare changing? How is access to funding changing? How are biopharma
companies affected, and how are they adjusting their general business and
dealmaking strategies?
- Spectrum has advised the industry to adapt to inevitable changes in the
industry. What are the promising strategies and new directions for
biopharma companies? How can companies turn challenges into opportunities?
Scope
- Events: political change in the United States and United Kingdom,
effects of the economy on the industry' s fortunes, new moves on the lifestyle
drugs landscape, new competitive considerations in the emerging market of
China.
- Dealmaking: deal type, deal value, deal focus, most active
companies, therapeutic areas.
- Generics: related deals, biosimilars, Big Pharma participation,
early competition for clopidogrel, opening of the Japanese market.
- Strategy: the varied affect of the economy on biotechs versus Big
Pharma; new imperatives in the response to the economy; new scrutiny of Big
Pharma responses to generic competition.
- Expert commentaries: generics industry perspectives, strategy
perspectives, U.K. policy news perspective, Japanese biosimilar industry news
perspective, Chinese intellectual property news perspective, Lilly' s
fourth-quarter dealmaking strategy perspective.
Mentioned in This Spectrum Report
- Companies
- Abbott
- Acino
- Actavis
- Actavis Totowa
- AFFiRiS
- Affymetrix
- Allergan
- Archemix
- Aska
- Aspen
- AstraZeneca
- AtheroGenics
- Bayer
- Biogen Idec
- BioVest
- Bristol-Myers Squibb
- Bristol-Myers Squibb Pakistan
- Caraco
- Cel-Sci
- Cephalon
- Chad
- Chugai
- CT Arzneimittel
- CureMark
- Cyntellect
- Daiichi Sankyo
- Deciphera Pharmaceuticals
- Dynavax Technologies
- Eisai
- Ethicon
- Exelixis
- Genelabs Technologies
- Genentech
- Genzyme
- Geron
- GlaxoSmithKline
- GlycArt Biotechnology
- HealthMedia
- Hexal
- ImClone
- Janssen Pharmaceutica
- Johnson & Johnson
- Jointown Group
- Lev
- LGE Performance Systems
- Eli Lilly
- Kissei Seiyaku
- Kowa
- Lpath Therapeutics
- Lupin
- MAP Pharmaceuticals
- MDRNA
- MedImmune
- Medivation
- Memory Pharmaceuticals
- Mentor
- Merck
- Merck BioVentures
- Merck Generics
- Merck KGaA
- Merck Serono
- MicroIslet
- Mylan
- Neuropharm
- Nippon Chemical Research
- Novartis
- Novocell
- OMRIX Biopharmaceuticals
- OncoGenex
- Orchestra Therapeutics
- Osiris Therapeutics
- Otsuka
- Pfi zer
- PGx Health
- Ranbaxy
- Ratiopharm
- ReNeuron
- Roche
- Sandoz
- Sanofi -Aventis
- Schwarz Pharma
- Schweizerhall
- Shanghai Pharma
- Sinopharm
- Spectrum Pharmaceuticals
- Strides-Arcolab
- Sun Pharmaceutical Industries
- Synta Pharmaceuticals
- Teva
- Thiakis
- Viropharma
- WuXi PharmaTech
- Wyeth
- Zentiva
- Zydus-Cadila
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Events Perspective
- On the Political Front: Focus on Themes of the U.S. Elections
- Expanded Access
- Cost Containment
- Cost-Effective, Quality Care
- Support for Innovation
- On the Economic Front: Quantifying the Impact of the Recession
- On the Approvals Front: Latisse Became the Latest Entry in the Lifestyle
Drugs Category
- On the International Front: Focus on Chinese Pharma Manufacturing
- Deals Perspective
- Deals by Company
- Deal Type
- Acquisitions
- Collaborations and Licensing
- Deals by Therapeutic Area - Oncology Focus
- Product Deals
- Generics Perspective: Pro-Generics Governments Boost the Generics Industry
- Increased Big Pharma Involvement in Generics
- U.S. Biosimilars Guidelines Delayed - For Now
- FDA Clampdowns - A Reaction to the Heparin Fiasco?
- Generic Plavix Reaches European Market Early Through a Legal Loophole
- Japanese Generics Market Starts to Open
- Strategy Perspective: Global Economic Crisis Is a Prelude to Greater
Challenges for Biopharma
- Biotech Sector: Cash Crunch, Company Crashes, and a Cull
- Pharma Sector: Missing a Master Plan for Necessary Transformation
- Pending Challenges for the Industry
Tables
- 1. Targets of Select Key Cost-Containment Measures in the Major Markets
- 2. Select PGx-Based Diagnostic Tests
- 3. Select Companies Working on Stem Cell Technologies and Therapies
- 4. Select Drugs in Development for Autism
- 5. Worldwide 2007 Sales of Select “Lifestyle” Drugs
- 6. Leading Domestic and Multinational Pharmaceutical Companies in China
- 7. Key Fourth-Quarter Findings of Decision Resources' Emerging Markets
Research and Analysis
- 8. Company Dealmaking Activity, Q4 2008
- 9. Select Big Pharma Acquisitions, Q4 2008
- 10. Select Big Pharma Collaborations, Q4 2008
- 11. Select Big Pharma Licensing, Q4 2008
- 12. Select Fourth Quarter Oncology Deals, 2008
- 13. Biosimilar Agents in the European Union and the United States
- 14. Generic Expansion into Japan, Q4 2008
Figures
- 1. Qualitative Assessment of Implications of U.S. Healthcare Reform for
Biopharma
- 2. Healthcare Statistics in the United States Versus Select Nations That
Provide Universal Health Insurance
- 3. Year in Review: Market Sector Stock Indices
- 4. Impact of Cost of Care on Access to Care in the United States Versus
Select Nations That Provide Universal Health Insurance
- 5. Fourth-Quarter 2008 U.S. Drug Approval Tallies and Highlights
- 6. Volume of Pharma and Biotech Deals, 2006-2008
- 7. Pharma and Biotech Deals Valued Over $100MM, 2006-2008
- 8. Largest Deals of Q4 2008, by Value
- 9. Therapeutic Area Focus of Deals, Q4 2008
- 10. Product Dealmaking Activities Between Companies, Q4 2008
- 11. Phase of Development of 54 Inlicensed Products, Q4 2008
- 12. Categories of Inlicensed Products, Q4 2008
- 13. Most Important Issues and Labeling Requirements for Regulatory
Authorities
- 14. Extensive Layoffs in the Pharmaceutical Industry, 2007-2008
Expert Commentaries
- Prospects for Improved Access to Innovative Medicines in the United Kingdom
- Outlook for Foreign Pharma in the Face of China' s New Patent Law
- Gilding Lilly? A Look at the ImClone Acquisition
- Biosimilars in Japan: The Threat Level Is Low
|
